FDA Brief

Warning letters Devices

FDA warning letter to

Thermoteknix System Limited

High riskIssued Mar 4, 2021Posted Mar 4, 2021Center for Devices and Radiological Health

FDA warned Thermoteknix that its FevIR Scan 2 COVID-19 temperature-screening device was adulterated and misbranded and sold in the U.S. without FDA authorization.

What happened

FDA reviewed Thermoteknix's website on February 22, 2021, and its Twitter, Vimeo, and Facebook pages, which directed consumers to the website. FDA found the website offered the FevIR Scan 2 for sale in the United States with statements that it helps fight the spread of COVID-19 and provides temperature screening and face mask detection. FDA said the product was offered without marketing approval, clearance, or authorization.

What FDA found

  1. The FevIR Scan 2 is a device intended to diagnose or prevent COVID-19 because the company's website and social media said it helps fight the spread of coronavirus.

    section 201(h) of the Act, 21 U.S.C. § 321(h)
  2. The company offered the device for sale in the United States without FDA marketing approval, clearance, or authorization.

    section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B)
  3. The company did not have an approved premarket approval application or an approved investigational device exemption for the product.

    section 515(a), 21 U.S.C. § 360e(a); section 520(g), 21 U.S.C. § 360j(g)
  4. FDA said the product was misbranded because the company did not notify FDA of its intent to introduce the product into interstate commerce for commercial distribution as required by 510(k).

    section 502(o), 21 U.S.C. § 352(o); section 510(k), 21 U.S.C. § 360(k)
  5. FDA said introduction or delivery for introduction of the product into interstate commerce is prohibited.

    section 301(a), 21 U.S.C. § 331(a)

What FDA wants

FDA asked the company to take immediate action to stop selling the product for COVID-19 and to email FDA within 48 hours describing steps taken to address the violations and prevent recurrence, or explain any delay.

Who should pay attention

  • U.S. businesses using temperature-screening cameras
  • medical device distributors and importers
  • marketing teams making COVID-19 claims

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. AseptiKits, LLC

    AseptiKits marketed unapproved sterile-preparation device kits without FDA clearance or approval, FDA says.

    High risk
  2. Happiest Baby, Inc.

    FDA says Happiest Baby marketed unapproved SNOO sleep sacks and hospital bundle and mishandled complaints.

    High risk
  3. Estar Technologies Ltd

    FDA warns Estar Technologies over selling seven unapproved PRP/PRF device kits in the U.S. without clearance or approval.

    High risk
  4. ProDx Health

    FDA warns ProDx Health that its HIV sample self-collection kits are sold without marketing authorization.

    High risk